课题基金 / 基金详情

SPECIFIC INTEGRIN ALPHA 4 CYTOPLASMIC TAIL FUNCTIONS

SPECIFIC INTEGRIN ALPHA 4 CYTOPLASMIC TAIL FUNCTIONS
特定整合素 ALPHA 4 细胞质尾部功能
批准号:
2900759
负责人:
MARTIN E HEMLER
金额:
$28.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-08-01 至 2000-03-31

项目摘要

项目成果

MARTIN E HEMLER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the Applicant's Abstract): The cytoplasmic domain of the integrin alpha4 subunit differs markedly from other alpha chain cytoplasmic domains with respect to focal adhesion formation, and this may account for increased cell migration but decreased cell spreading, adhesion strengthening, plasma membrane stiffness, and PIP4,5 synthesis. The principal investigator hypothesizes that distinctive structural features within the alpha-4 tail produce its specialized functions in coordination with specific biochemical associations and signaling pathways. Furthermore the principal investigator hypothesizes these unique features of the alpha-4 tail are critical in vivo for normal lymphocyte physiology and inflammation. To test this hypothesis he will: 1) evaluate alpha-4 tail mutants on blood cells in vivo; 2) use a panel of mutants to determine the exact tail residues responsible for migration, adhesion strengthening, coclustering with known cytoskeletal proteins and other specialized functions of the integrin alpha-4 tail; and 3) compare phosphoinositide synthesis and other signaling functions of wild type and mutant alpha-4 in K562 cells, CHO cells, and primary lymphocytes derived from RAG-2 chimeric mice. The use of minimal mutations with maximal functional effect will allow him to link conclusively alpha-4 specific positive and negative functional effects with specific colocalized proteins and specific signaling pathways Also he will have a unique opportunity to carry out definitive in vivo evaluations of the alpha-4 tail during normal blood maturation and during inflammation. The availability of primary mouse lymphocytes expressing mutant and wild type alpha-4 will allow an expanded analysis of alpha-4 specific signaling pathways.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1084/jem.186.8.1347
发表时间: 1997-10-20
期刊: JOURNAL OF EXPERIMENTAL MEDICINE
影响因子: 15.3
作者: [Yauch, RL, Felsenfeld, DP, Kraeft, SK, Chen, LB, Sheetz, MP, Hemler, ME]
通讯作者: Hemler, ME
DOI: 10.1083/jcb.128.6.1243
发表时间: 1995-03
期刊: The Journal of cell biology
影响因子: --
作者: [Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME, Springer TA]
通讯作者: Springer TA
Minimum alpha chain cytoplasmic tail sequence needed to support integrin-mediated adhesion.
支持整合素介导的粘附所需的最小α链胞质尾序列。
DOI: --
发表时间: 1994
期刊: The Journal of biological chemistry
影响因子: --
作者: [Kassner,PD, Kawaguchi,S, Hemler,ME]
通讯作者: Hemler,ME
Role of the alpha subunit cytoplasmic domain in regulation of adhesive activity mediated by the integrin VLA-2.
α亚基胞质结构域在整合素 VLA-2 介导的粘附活性调节中的作用。
DOI: --
发表时间: 1993
期刊: The Journal of biological chemistry
影响因子: --
作者: [Kawaguchi,S, Hemler,ME]
通讯作者: Hemler,ME
Targeting of tumor cell DHHC3 to enhance anti-cancer immunity
  • 批准号:
    10116321
  • 项目类别:
  • 资助金额:
    $40.02万
  • 财政年份:
    2020
  • 负责人:
    MARTIN E HEMLER
  • 依托单位:
Targeting of tumor cell DHHC3 to enhance anti-cancer immunity
  • 批准号:
    9884868
  • 项目类别:
  • 资助金额:
    $40.02万
  • 财政年份:
    2020
  • 负责人:
    MARTIN E HEMLER
  • 依托单位:
Targeting of tumor cell DHHC3 to enhance anti-cancer immunity
  • 批准号:
    10357889
  • 项目类别:
  • 资助金额:
    $39.22万
  • 财政年份:
    2020
  • 负责人:
    MARTIN E HEMLER
  • 依托单位:
Targeting of tumor cell DHHC3 to enhance anti-cancer immunity
  • 批准号:
    10578679
  • 项目类别:
  • 资助金额:
    $39.22万
  • 财政年份:
    2020
  • 负责人:
    MARTIN E HEMLER
  • 依托单位:
海外基金